We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Harris Williams & Co. Advises Caprion in its Sale to CGP
News

Harris Williams & Co. Advises Caprion in its Sale to CGP

Harris Williams & Co. Advises Caprion in its Sale to CGP
News

Harris Williams & Co. Advises Caprion in its Sale to CGP

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Harris Williams & Co. Advises Caprion in its Sale to CGP"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Harris Williams & Co. has announced the sale of Caprion Proteomics, Inc. (Caprion), the leading provider of integrated proteomic biomarker and target identification solutions and immune monitoring services, to Chicago Growth Partners (CGP).

Caprion was a portfolio company of Great Point Partners (GPP). Harris Williams & Co. acted as an advisor to Caprion.

The transaction closed on July 19, 2012 and was led by James Clark, Turner Bredrup, Geoff Smith, Whit Knier and Paul Hepper from the firm's Healthcare & Life Sciences (HCLS) Group.

"Caprion has established itself as the market leader in providing outsourced proteomic biomarker discovery and immune monitoring services for its growing list of blue-chip pharmaceutical and biotechnology clients. Caprion is well positioned as the pharmaceutical industry continues to outsource critical elements of the drug development process to maximize returns on its research and development spend," said James Clark, a managing director in Harris Williams & Co.'s HCLS Group.

Caprion is the leading provider of proteomics services to many of the largest and most successful pharmaceutical and biotechnology companies, as well as several government research institutions.

Caprion's key services include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv) advanced immune monitoring services, and (v) clinical diagnostic product development.

The company's proprietary CellCarta technology is the leading biomarker discovery and validation platform in the growing field of proteomics, and has overcome technical limitations of earlier proteomics technologies by developing and effectively putting into industrial practice a powerful proteomics engine for highly multiplexed, unbiased measurement of protein abundance differences across large sample sets.

GPP, based in Greenwich, CT, is a leading healthcare investment firm with approximately $400 million of equity capital under management. The firm manages capital in public and private equity funds.

GPP has provided growth equity, growth recapitalization and management buyout financing to more than 100 healthcare companies.

The private equity fund invests in profitable companies across all sectors of the healthcare industry including behavioral health, biologics manufacturing, healthcare services, hospital outsourcing, information technology, life sciences, media and reagents, medical devices, rehabilitation, specialty pharmaceuticals and workers' compensation.

For over 25 years and across more than 100 growth companies, the principals of CGP have partnered with quality management teams to help facilitate their growth objectives.

CGP executes its growth-focused investment strategy across four industries: education, tech-enabled services, healthcare and industrial growth. CGP currently manages $1.2 billion of committed capital and has offices in Chicago and La Jolla.

Advertisement